Results 231 to 240 of about 371,513 (350)

Molecular stratification of antiphospholipid syndrome through integrative analysis of the whole‐blood RNA transcriptome

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Antiphospholipid syndrome (APS) is a thrombo‐inflammatory disorder characterized by clinical and mechanistic heterogeneity that complicates early diagnosis and hinders targeted treatment. We aimed to identify distinct molecular endotypes among antiphospholipid antibody (aPL)‐positive patients using whole‐blood transcriptomics.
Amala Ambati   +13 more
wiley   +1 more source

Systemic Lupus Erythematosus and Acute Transverse Myelitis: An Unusual Association-A Case Report. [PDF]

open access: yesCase Rep Med
Djamilatou Sawadogo BA   +6 more
europepmc   +1 more source

Hypertension and its complications in a young man with autoimmune disease [PDF]

open access: yes, 2017
Basile, Jan N.   +9 more
core   +1 more source

A cooperative release of mitochondrial DNA from platelets and neutrophils drives an interferon signature in systemic sclerosis

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Mitochondria are organelles with a hypomethylated circular genome. Mitochondrial DNA (mtDNA) in the systemic circulation has been implicated in inflammation. This study investigates the role of circulating DNA in systemic sclerosis (SSc) and the cellular mechanisms governing its release.
Stavros Giaglis   +9 more
wiley   +1 more source

A Case Report of Discoid Lupus Erythematosus Mimicking Skin Infection. [PDF]

open access: yesReports (MDPI)
Stoyanova Z   +4 more
europepmc   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP‐SC Study

open access: yesArthritis &Rheumatology, Accepted Article.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate‐to‐severe SLE activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 ...
Susan Manzi   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy